Results 91 to 100 of about 32,769 (202)

Ustekinumab for the treatment of psoriatic arthritis: an update

Clinical, Cosmetic and Investigational Dermatology, 2014
Parastoo Davari, Michael S Leo, Faranak Kamangar, Nasim Fazel Department of Dermatology, University of California, Davis, CA, USA Abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients ...
Davari P, Leo MS, Kamangar F, Fazel N
doaj  

Psoriatic Arthritis Is an Indicator of Significant Renal Damage in Patients with Psoriasis: An Observational and Epidemiological Study

International Journal of Inflammation, 2017
Background. Psoriasis affects joints in around 30% of the patients. Recent studies have demonstrated an increased risk of essential hypertension, ischemic heart disease, and stroke in psoriatic patients.
Abidullah Khan, Iqbal Haider, Maimoona Ayub, Mohammad Humayun   +3 more
doaj   +1 more source

Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity. [PDF]

J Pers Med, 2022
Dorochow E, Köhm M, Hahnefeld L, Gurke R.   +3 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Clinical &Experimental Allergy, EarlyView.
This systematic review and meta‐analysis of 50 cohort studies summarises the real‐world effectiveness and safety of systemic JAK inhibitors for the treatment of moderate to severe atopic dermatitis. ABSTRACT Objective The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic ...
Yunha Kim, Gayeong Seo, Jacob J. E. Koopman, Jeong Yee   +3 more
wiley   +1 more source

Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. [PDF]

Lancet Reg Health Eur, 2022
Scott IC, Whittle R, Bailey J, Twohig H, Hider SL, Mallen CD, Muller S, Jordan KP.   +7 more
europepmc   +1 more source

A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase‐4. Patients and Methods A phase IIb randomized, double‐blind, placebo‐controlled study evaluating the effects of apremilast or placebo in patients with NE.
Alexander Böhner, Peter Seiringer, Viktoria Kleeberger, Danielle Rogner, Christian Oesterlin, Tilo Biedermann, Kilian Eyerich, Felix Lauffer   +7 more
wiley   +1 more source

Vasculitis associated with psoriatic arthritis: a case report

Egyptian Rheumatology and Rehabilitation
Background Psoriatic arthritis is a chronic inflammatory condition associated with psoriasis, which affects joints. The coexistence of vasculitis, an inflammation of blood vessels, with psoriatic arthritis is rare, highlighting a complex interplay ...
Mehdi Jafarpour, Bita Rahbari, Bahareh Mehramuz, Sara Daneshvar   +3 more
doaj   +1 more source

Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'. [PDF]

Ann Rheum Dis, 2023
Dumoulin QA, Matthijssen XME, Wouters F, Krijbolder DI, Niemantsverdriet E, van der Helm-van Mil AHM.   +5 more
europepmc   +1 more source

Comprehensive Literature Review Evaluating the Use, Safety, and Efficacy of Subcutaneous Methotrexate in the Treatment of Adult Patients With Moderate‐To‐Severe Plaque‐Type Psoriasis

International Journal of Dermatology, EarlyView.
ABSTRACT Methotrexate (MTX) is a conventional systemic therapy widely used to treat chronic plaque‐type psoriasis, a chronic inflammatory skin disease that significantly impacts patients' quality of life. MTX can be administered orally or subcutaneously. Over the past decades, the use of subcutaneous versus oral MTX has been a subject of ongoing debate
Manuelle Viguier, José‐Manuel Carrascosa‐Carrillo, Pariyawan Rakvit, Maria‐Magdalena Constantin, Alice‐Anaïs Varlet, Solenn Le Clanche, Linda A. W. Verhagen, Wolf‐Henning Boehncke   +7 more
wiley   +1 more source

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [PDF]

Arthritis Res Ther, 2022
Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A.   +8 more
europepmc   +1 more source